Kraj: Unia Europejska
Język: angielski
Źródło: EMA (European Medicines Agency)
inactivated Coxiella burnetii vaccine, strain Nine Mile
CEVA Santé Animale
QI02AB
inactivated Coxiella burnetii vaccine
Goats; Cattle
Immunologicals for bovidae, Inactivated bacterial vaccines (including mycoplasma, toxoid and chlamydia)
Cattle: , For the active immunisation of cattle to lower the risk for non-infected animals vaccinated when non-pregnant to become shedder (5 times lower probability in comparison with animals receiving a placebo), and to reduce shedding of Coxiella burnetii in these animals via milk and vaginal mucus., Onset of immunity: not established., Duration of immunity: 280 days after completion of the primary vaccination course. , Goats: , For the active immunisation of goats to reduce abortion caused by Coxiella burnetii and to reduce shedding of the organism via milk, vaginal mucus, faeces and placenta., Onset of immunity: not established., Duration of immunity: one year after completion of the primary vaccination course.
Revision: 7
Authorised
2010-09-30
16 B. PACKAGE LEAFLET 17 PACKAGE LEAFLET: COXEVAC SUSPENSION FOR INJECTION FOR CATTLE AND GOATS 1. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER AND OF THE MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE, IF DIFFERENT Marketing authorisation holder: CEVA Sante Animale 10 avenue de la Ballastiere 33500 Libourne FRANCE Manufacturer responsible for batch release: CEVA-Phylaxia Veterinary Biologicals Co. Ltd. Szállás u. 5 1107 Budapest HUNGARY 2. NAME OF THE VETERINARY MEDICINAL PRODUCT COXEVAC suspension for injection for cattle and goats 3. STATEMENT OF THE ACTIVE SUBSTANCE(S) AND OTHER INGREDIENT(S) Each ml contains: ACTIVE SUBSTANCE: Inactivated _Coxiella burnetii,_ strain Nine Mile > 72 QF Units* *QF (Q fever) Unit: relative potency of phase I antigen measured by ELISA in comparison with a reference item. EXCIPIENTS: Thiomersal < 120 μg. Whitish, opalescent, homogeneous suspension. 4. INDICATION(S) Cattle: For the active immunisation of cattle to lower the risk for non-infected animals vaccinated when non- pregnant to become shedder (5 times lower probability in comparison with animals receiving a placebo), and to reduce shedding of _Coxiella burnetii_ in these animals via milk and vaginal mucus. Onset of immunity: not established. Duration of immunity: 280 days after completion of the primary vaccination course. Goats: For the active immunisation of goats to reduce abortion caused by _Coxiella burnetii_ and to reduce shedding of the organism via milk, vaginal mucus, faeces and placenta. Onset of immunity: not established. Duration of immunity: one year after completion of the primary vaccination course. 18 5. CONTRAINDICATIONS None. 6. ADVERSE REACTIONS Cattle: It was very common to see in laboratory trials a palpable reaction of maximum diameter of 9 to 10 cm at the injection site, which may last for 17 days. The reaction gradually reduces and disappears without need for treatment. Systemic signs as lethargy, hyperthermia and/or anorexia have been observed rarely in post marketing Przeczytaj cały dokument
1 _ _ ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 2 1. NAME OF THE VETERINARY MEDICINAL PRODUCT COXEVAC suspension for injection for cattle and goats 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each ml contains: ACTIVE SUBSTANCE: Inactivated _Coxiella burnetii,_ strain Nine Mile > 72 QF Units* *QF (Q fever) Unit: relative potency of phase I antigen measured by ELISA in comparison with a reference item. EXCIPIENT: Thiomersal < 120 μg. For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Suspension for injection. Whitish, opalescent, homogeneous suspension. 4. CLINICAL PARTICULARS 4.1 TARGET SPECIES Cattle and goats 4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES Cattle: For the active immunisation of cattle to lower the risk for non-infected animals vaccinated when non- pregnant to become shedder (5 times lower probability in comparison with animals receiving a placebo), and to reduce shedding of _Coxiella burnetii_ in these animals via milk and vaginal mucus. Onset of immunity: not established. Duration of immunity: 280 days after completion of the primary vaccination course. Goats: For the active immunisation of goats to reduce abortion caused by _Coxiella burnetii_ and to reduce shedding of the organism via milk, vaginal mucus, faeces and placenta. Onset of immunity: not established. Duration of immunity: one year after completion of the primary vaccination course. 4.3 CONTRAINDICATIONS None. 3 4.4 SPECIAL WARNINGS FOR EACH TARGET SPECIES Vaccination of animals already infected at the time of vaccination will have no adverse effect. No efficacy data are available concerning the use of COXEVAC in male animals. However, in safety laboratory trials, the use of COXEVAC in males proved to be safe. In the case that it is decided to vaccinate the whole herd, it is advisable to vaccinate the male animals at the same time. There are no benefits of the vaccine (as described in the indications for cattle), when used in infected and/or pregnant cows. The biological significance of the levels of r Przeczytaj cały dokument